PegBio Co., Ltd.

PegBio Co., Ltd. logo
🇭🇰Hong Kong, China
Ownership
Holding
Established
2008-05-13
Employees
51
Market Cap
-
Website
http://www.pegbio.com
Clinical Trials
Related News

Dose-finding of PB-119 Administered Subcutaneously Once-weekly Versus Placebo in Drug-naïve T2DM Subjects

First Posted Date
2018-05-11
Last Posted Date
2020-01-22
Lead Sponsor
PegBio Co., Ltd.
Target Recruit Count
251
Registration Number
NCT03520972
Locations
🇨🇳

Peking University People's Hospital, Peking, China

MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM

First Posted Date
2017-03-07
Last Posted Date
2018-04-20
Lead Sponsor
PegBio Co., Ltd.
Target Recruit Count
40
Registration Number
NCT03072407
Locations
🇺🇸

Clinical Pharmacology of Miami, Inc., Miami, Florida, United States

🇺🇸

Frontage Clinical Services. Inc., Hackensack, New Jersey, United States

Continuous Multiple Dose PB-119 Injection in Health Volunteers

Phase 1
Completed
Conditions
Type2 Diabetes Mellitus
Interventions
Biological: PB-119 injection
First Posted Date
2017-02-23
Last Posted Date
2017-02-23
Lead Sponsor
PegBio Co., Ltd.
Target Recruit Count
36
Registration Number
NCT03062774
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

Clinical Trial for PB-119 in Subjects With Type 2 Diabetes Mellitus

First Posted Date
2017-02-23
Last Posted Date
2017-02-23
Lead Sponsor
PegBio Co., Ltd.
Target Recruit Count
36
Registration Number
NCT03059719
Locations
🇨🇳

No.1 Hospital of Peking University, Beijing, Beijing, China

Clinical Trial for PB-119 in Healthy Subjects (Phase I)

Phase 1
Completed
Conditions
Type II Diabetes
Interventions
Drug: PB-119
First Posted Date
2014-03-11
Last Posted Date
2017-02-14
Lead Sponsor
PegBio Co., Ltd.
Target Recruit Count
70
Registration Number
NCT02084251
Locations
🇨🇳

Peking University First Hospital, Beijing, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy